Selective glucagon-like-peptide-2 (GLP-2) analogues

US8642727B2 · kind B2 · utility

Assignee

• Zealand Pharma A/S · DK

Inventors

• Bjarne Due Larsen · Roskilde, DK
• Yvette Miata Petersen · Avenue Madeleine, DK

Key dates

• Filing date: Nov 8, 2007
• Grant date: Feb 4, 2014
• Expiry date: Feb 22, 2030

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K14/605
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

GLP-2 analogues are disclosed which comprise one of more substitutions as compared to h[Gly2]GLP-2 and which may have the property of an increased small intestine/colon and stomach/colon selectivity. More particularly, preferred GLP-2 analogues disclosed herein comprise substitutions at one or more of positions 11, 16, 20, 24 and/or 28 of the wild-type GLP-2 sequence, optionally in combination with further substitutions at position 2 and one or more of positions 3, 5, 7, and 10, and/or a deletion of one or more of amino acids 31 to 33 and/or the addition of a N-terminal or C-terminal stabilizing peptide sequence. The analogues are particularly useful for the prophylaxis or treatment of stomach and bowel-related disorders and for ameliorating side effects of chemotherapy.